Pfizer and BioNTech announced on Friday that the COVID-19 vaccine could be remade in “about 100 days” to counter new variants of the CCP virus that could be invaded through the vaccine.
A US-based pharmaceutical company has more in a statement obtained by news agency Reuters about B.1.1.529, a new variant of the virus called “Omicron” by the World Health Organization (WHO). The data will have to remake the vaccine.
“We understand the concerns of the experts and immediately began investigating variant B.1.1.529,” BioNTech said in a statement when asked for comment.
“We expect more data from laboratory tests within two weeks at the latest,” he added. “These data provide more information on whether B.1.1.529 may be an escape variant that may require vaccine adjustment if the variant spreads globally. Will provide. “
According to an early study of variants published in statement By WHO, the agency CCP (Chinese Communist Party) virus This strain has an increased risk of reinfection compared to other mutant strains such as the Delta and Alpha strains. The new strain was first detected in Botswana and South Africa earlier this month.
At the global level, authorities have warned Omicron, and many countries, including the United States and the United Kingdom, have already tightened border control, criticized by South African Health Minister Joe Fara.
This week, the US Centers for Disease Control and Prevention (CDC) confirmed that cases of South African CCP virus variants have not yet been confirmed in the United States.
In addition to Pfizer, Johnson & Johnson (J & J) has also announced that it has begun testing the effectiveness of shots against the B.1.1.529 variant.
“We are carefully monitoring newly emerging COVID-19 virus strains with variations of the SARS-CoV-2 peaplomer and have already tested the efficacy of the vaccine against the new and rapidly spreading mutants first detected in South Africa. “We are,” said a J & J spokeswoman. I told the press.
In a statement, Moderna is working to advance booster candidates for new variants, testing high doses of existing boosters and studying other booster candidates designed to protect against multiple variants. I said that I am doing it.
“The licensed booster vaccine represents the only strategy currently available to promote weakened immunity,” said Moderna.
from NTD News